Literature DB >> 3779618

Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases.

N L Carlsen, I J Christensen, H Schroeder, P V Bro, G Erichsen, B Hamborg-Pedersen, K B Jensen, O H Nielsen.   

Abstract

Multivariate analysis on an unselected patient population consisting of all 253 children treated for neuroblastoma in Denmark during 1943 to 1980 shows that stage, age, and treatment given are independent prognostic variables. Calendar year of diagnosis, sex of the patient, and site of primary tumor were not significant prognostic factors. Further analysis shows that multimodal treatment with surgery, irradiation, and chemotherapy, especially in patients older than 1 year of age with Stage II disease, has influenced the survival significantly. The fact that age at diagnosis and the administration of chemotherapy have independent prognostic significance can be explained by the theory that all neuroblastomas are virtually congenital; therefore, the difference in age at diagnosis largely reflects the difference in growth rates of the tumor. Thus, according to this theory, age may be a measure of the probability of micrometastases in addition to the clinical extent or stage of the disease, as it represents the duration of the disease. Additional chemotherapy may thus have eradicated these micrometastases in the older children, since the age influence on Stage II disease disappeared when multimodal treatment was given in this study. The implications for treatment policy are discussed in view of this theory.

Entities:  

Mesh:

Year:  1986        PMID: 3779618     DOI: 10.1002/1097-0142(19861215)58:12<2726::aid-cncr2820581229>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Authors:  Kieuhoa T Vo; Katherine K Matthay; John Neuhaus; Wendy B London; Barbara Hero; Peter F Ambros; Akira Nakagawara; Doug Miniati; Kate Wheeler; Andrew D J Pearson; Susan L Cohn; Steven G DuBois
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas.

Authors:  N L Carlsen; K Ornvold; I J Christensen; H Laursen; J K Larsen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Incidence, ocular manifestations, and survival in children with neuroblastoma: a population-based study.

Authors:  Stephen J Smith; Nancy N Diehl; Brian D Smith; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2010-02-10       Impact factor: 5.258

4.  Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Authors:  Youssef Al-Tonbary; Mohamed Badr; Ahmed Mansour; Usama El Safy; Shebl Saeed; Tamer Hassan; Rasha Elashery; Rofida Nofal; Ahmad Darwish
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

5.  IGF2 expression is a marker for paraganglionic/SIF cell differentiation in neuroblastoma.

Authors:  F Hedborg; R Ohlsson; B Sandstedt; L Grimelius; J C Hoehner; S Pählman
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Authors:  Daria Thompson; Kieuhoa T Vo; Wendy B London; Matthias Fischer; Peter F Ambros; Akira Nakagawara; Garrett M Brodeur; Katherine K Matthay; Steven G DuBois
Journal:  Cancer       Date:  2015-12-28       Impact factor: 6.860

7.  Trends in survival for childhood cancer in Britain diagnosed 1971-85.

Authors:  C A Stiller; K J Bunch
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

8.  Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study.

Authors:  H Schroeder; J Wacher; H Larsson; S Rosthoej; C Rechnitzer; B L Petersen; B L Pedersen; N L T Carlsen
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

9.  Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.

Authors:  T Philip; R Ladenstein; J M Zucker; R Pinkerton; E Bouffet; D Louis; W Siegert; J L Bernard; D Frappaz; C Coze
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

10.  How frequent is spontaneous remission of neuroblastomas? Implications for screening.

Authors:  N L Carlsen
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.